Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out

European Urology

Volumn 39, Issue SUPPL. 1, 2001, Pages 10-14

  Van Poppel, Hein ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Androgen antagonists; Neoadjuvant therapy; Prostatectomy; Prostatic neoplasms

Indexed keywords

CYPROTERONE ACETATE; ESTRAMUSTINE PHOSPHATE; PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER CELL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; FOLLOW UP; HORMONAL THERAPY; HUMAN; INFORMED CONSENT; LIFE EXPECTANCY; MALE; PATIENT EDUCATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0035214640     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052544     Document Type: Conference Paper

References (49)

1. Radical surgery for prostatic cancer
2. Prostate cancer consensus hampered by lack of data
3. Localised prostate cancer: A Scandinavian view
4. The indications, rationale and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer
5. Neoadjuvant hormonal treatment before radical prostatectomy
6. Impact of radical prostatectomy in the management of clinically localized disease
7. Correlation of pathologic findings with progression after radical retropubic prostatectomy
8. Prognostic significance of positive surgical margins in radical prostatectomy specimens
9. Cancer control and quality of life following anatomical radical prostatectomy: Results at 10 years
10. 5-Year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
11. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary
12. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localised prostate cancer
13. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localised prostatic adenocarcinoma
14. Pathology of androgen deprivation therapy in prostate carcinoma: A comparative study of 173 patients
15. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer
16. Histologic changes in prostate carcinomas treated with leuprolide (luteinising hormone-releasing hormone effect). Distinction from poor tumour differentiation
17. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study
18. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies
19. Long-term outcome following preoperative androgen deprivation therapy for clinical stage T3 prostate cancer
20. Hormonal treatment before radical prostatectomy: A 3-year follow-up
21. Effect of combination endocrine therapy on normal prostate, prostatic intraepithelial neoplasia and prostatic adenocarcinoma
22. Prognostic factors in patients with prostate cancer treated with neoadjuvant hormonal therapy and radical prostatectomy
23. Supersensitive PSA-monitored neoadjuvant hormone treatment of clinically localised prostate cancer: Effects on positive margins, tumour detection and epithelial cells in bone marrow
24. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumour volume: Three versus six months of endocrine therapy
25. Effect of androgen deprivation on epithelial and mesenchymal tissue components in localised prostate cancer
26. Neoadjuvant androgen ablation in localised prostatic cancer, a meta analysis of randomized trials
27. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial
28. The role of neoadjuvant androgen deprivation prior to radical prostatectomy
29. Downstaging of localised prostate cancer by neoadjuvant therapy with flutamide and Lupron: The first controlled and randomized trial
30. Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience
31. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure
32. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localised prostate cancer: Results of a phase II study
33. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localised prostate cancer
34. Neoadjuvant androgen ablation prior to radical prostatectomy (CUOG P-92). 24 month post-treatment PSA results
35. Neoadjuvant hormonal treatment prior to radical prostatectomy: Facts and open questions
36. Neoadjuvant hormonal blockade before radical prostatectomy: 3-4 years' follow-up evaluation of an European multicentric randomized study
37. 0 prostatic carcinoma
38. Radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 months results
39. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
40. Neoadjuvant hormonal deprivation before radical prostatectomy
41. Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinising hormone-releasing hormone agonist
42. Neoadjuvant hormonotherapy does not facilitate radical prostatectomy
43. A randomized comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
44. Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: Biochemical and pathological effects
45. Results of a European randomized study comparing radical prostatectomy and radical prostatectomy plus neoadjuvant hormonal combination therapy in stage T2-3N0M0 prostatic carcinoma
46. Update on neoadjuvant androgen deprivation therapy and radical prostatectomy in localised prostate cancer
47. Influence of neoadjuvant hormonotherapy on PSA response and pathological stage at radical prostatectomy
48. Neoadjuvant treatment before radical prostatectomy decreases the number of positive margins in cT2-T3 but has no impact on PSA progression or survival in cT2-T3
49. Neoadjuvant combined androgen deprivation therapy in locally confined prostatic carcinoma: 3 to 4 years of follow-up of a European randomized study